Effect of Dihydroarteannuin on transplantation tumor growth in C57BL/6J mice with lewis lung cancer

Abstract

Abstract: AIM:To explore the anti-tumor effect and the mechanism of dihydroarteannuin in C57BL/6J mice with lewis lung cancer.METHODS:Fifty C57BL/6J mice subcutaneously planted with 3LL lung cancer cells (2×10⁶)were randomly divided into 5 groups :blank control group, same volume of normal saline group, positive control DDP group, low, middle and high dose dihydroarteannuin groups.Changes of body weight and inhibitory rate of tumor in each group were observed.The cell cycle and apoptosis rates were analyzed by flow cytometry.RESULTS:The body weights were decreased in middle and high dose group compared with NS group and the inhibitory rate of tumor were 53.50% and 59.24% respectively.FCM assay indicated that Dihydroarteannuin could induce apoptosis of lung cancer cell.At the same time, the number of G0G1 and G₂/M phase cells was decreased. Most of the cells were arrested in S1phase.CONCLUSION:Dihydroarteannuin has obviously effect on anti-tumor in C57BL/6J mice with lung cancer.Its possible mechanism might be involved in inducing cancer cell apoptosis.

Key words: Dihydroarteannuin, C57BL/6J mice, lung cancer, apoptosis, cell cycle

CLC Number:

R965.2

JIANG Yong-xin, WANG Qian, CHEN Xiao-qun, JIN Cong-guo, LI Jia, DENG Jing. Effect of Dihydroarteannuin on transplantation tumor growth in C57BL/6J mice with lewis lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(8): 891-894.

References 11

[1]	蒋永新, 王熙才, 金从国, 等.双氢青蒿素对人肺鳞癌细胞株YTMLC 抑制作用的实验研究[J].临床肿瘤学杂志, 2006, 11(10):730-734.
[2]	Lee J, Zhou HJ, Wu XH.Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells [J].Cancer Chemother Pharmacol, 2006, 57(2):213-220.
[3]	Chen HH, Zhou HJ, Wang WQ, et al.Antimalarial dihydroartemisinin also inhibits angiogenesis [J].Cancer Chemother Pharmacol, 2004, 53(5):423-432.
[4]	Yanachika E, Habte T, Oda D.Artemisinin:an alternative treatment for oral squamous cell carcinoma[J].Anticancer Res, 2004, 24(4):2153-2160.
[5]	Dell'Eva R, Pfeffer U, Vene R, et al.Inhibition of angiogenesis in vivo and growth of Kaposis sarcoma xenograft tumors by the anti-malarial artesunate[J].Biochem Pharmacol, 2004, 68(12):2359-2366.
[6]	Darzynkiewicz Z, Bruno S, Del Bino G, et al.Feature of apoptotic cells measured by flow cytometry[J].Cytometry, 1992, 13(8):795-808.
[7]	Darzynkiewicz Z, Bedner E, SmolewskIP.Flow cytometry in analysis of cell cycle and apoptosis[J].Semin Hematol, 2001, 38(2):179-193.
[8]	李红, 范晓磊.中药诱导肿瘤细胞凋亡的研究进展[J].医学综述, 2003, 9(3):135-137.
[9]	薛妍, 夏天, 赵建斌, 等.姜黄素对人肝癌细胞SMMC7721的抑制作用[J].第四军医大学学报,2000, 21(5):584-586.
[10]	左云飞, 张耀铮, 魏巍, 等.榄香烯对肝癌腹水瘤细胞系的抗瘤作用及对细胞周期的影响[J].中药药理与临床, 1999, 15(5):24-25.
[11]	Lin F, Qian ZY, Ding J, et al.Effect of dihydroartemisinin on the proliferation of MCF-7cell[J].Chin J New Drugs, 2002, 11(12):934-936.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[3]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[4]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[5]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[6]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[7]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[8]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[9]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[10]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[11]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[12]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[13]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[14]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[15]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.